Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
aduhelm save search
Biogen Submits Final Protocol for ADUHELM® (aducanumab-avwa) Phase 4 ENVISION Trial to FDA
Published: 2022-03-30 (Crawled : 12:20) - biospace.com/
BIIB | $201.91 4.52% 4.32% 3.3M
|
Health Technology
|
| O: 0.0%
H: 0.66%
C: -1.82%
aduhelm fda trial
Biogen Announces Peer-Reviewed Publication of ADUHELM® Phase 3 EMERGE and ENGAGE Data in The Journal of Prevention of Alzheimer’s Disease
Published: 2022-03-16 (Crawled : 16:00) - globenewswire.com
BIIB | $201.91 4.52% 4.32% 3.3M
|
Health Technology
|
| O: 1.96%
H: 1.5%
C: 1.28%
aduhelm alzheimer disease phase 3 merge alzheimer’s alzheimer's disease alzheimer's
Long-Term Phase 3 Data Show ADUHELM® Continues to Reduce Underlying Pathologies of Alzheimer’s Disease in Patients Treated for More Than Two Years
Published: 2022-03-16 (Crawled : 12:00) - globenewswire.com
BIIB | $201.91 4.52% 4.32% 3.3M
|
Health Technology
|
| O: 1.96%
H: 1.5%
C: 1.28%
aduhelm alzheimer disease phase 3 alzheimer’s alzheimer's disease alzheimer's
Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM®
Published: 2022-01-27 (Crawled : 13:30) - biospace.com/
BIIB | $201.91 4.52% 4.32% 3.3M
|
Health Technology
|
| O: 0.76%
H: 1.12%
C: -1.05%
aduhelm
Biogen Announces Reduced Price for ADUHELM® to Improve Access for Patients with Early Alzheimer’s DiseaseThe company to also implement cost-reduction measures.
Published: 2021-12-20 (Crawled : 13:30) - biospace.com/
BIIB | $201.91 4.52% 4.32% 3.3M
|
Health Technology
|
| O: 2.56%
H: 0.1%
C: -1.16%
aduhelm alzheimer als disease alzheimer’s alzheimer's
Update on the Phase 4 Confirmatory Study of ADUHELM®
Published: 2021-12-16 (Crawled : 13:00) - biospace.com/
BIIB | $201.91 4.52% 4.32% 3.3M
|
Health Technology
|
| O: 2.39%
H: 0.0%
C: 0.0%
aduhelm
Aduhelm Launch Trends Show Some Early Signs Of Progress As The Biogen Team Aims To Moderate Near-Term Expectations, According To Spherix Global Insights
Published: 2021-09-16 (Crawled : 11:33) - prnewswire.com
MS | News 0 d | $93.85 0.1% 0.0% 4.8M
|
Finance
|
| O: 0.46%
H: 0.64%
C: -1.0%
Cost, Confusion Proving Potentially Prohibitive in Aduhelm Rollout
Published: 2021-09-10 (Crawled : 16:00) - biospace.com/
MS | News 0 d | $93.85 0.1% 0.0% 4.8M
|
Finance
|
| O: 0.71%
H: 0.0%
C: 0.0%
potential
Biogen Giving Out Free Doses of Alzheimer’s Drug Aduhelm
Published: 2021-09-02 (Crawled : 18:00) - biospace.com/
MS | News 0 d | $93.85 0.1% 0.0% 4.8M
|
Finance
|
| O: 0.67%
H: 0.48%
C: -0.17%
alzheimer drug alzheimer’s alzheimer's
Biogen and Eisai Announce Design of ADUHELM ICARE AD-US Study, the First Real-World Observational Phase 4 Study in Alzheimer’s Disease at AAIC 2021
Published: 2021-07-29 (Crawled : 21:00) - biospace.com/
BIIB | $201.91 4.52% 4.32% 3.3M
|
Health Technology
|
| O: 0.24%
H: 0.58%
C: -1.74%
disease alzheimer alzheimer’s alzheimer's disease alzheimer's designation
Biogen to Present Data from ADUHELM and Alzheimer’s Disease Portfolio at 2021 Alzheimer’s Association International Conference
Published: 2021-07-23 (Crawled : 21:00) - globenewswire.com
BIIB | $201.91 4.52% 4.32% 3.3M
|
Health Technology
| Email alert
Add to watchlist
disease alzheimer conference alzheimer’s alzheimer's disease alzheimer's
FDA Approves Updated ADUHELM™ Prescribing Information to Emphasize Population Studied in Clinical TrialsADUHELM should be initiated in patients with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s dementia
Published: 2021-07-08 (Crawled : 13:00) - biospace.com/
BIIB | $201.91 4.52% 4.32% 3.3M
|
Health Technology
|
| O: -1.48%
H: 5.71%
C: 5.42%
disease alzheimer fda dementia clinical trials trial initiated fda approval alzheimer’s alzheimer's disease alzheimer's
FDA Approves Updated ADUHELM™ Prescribing Information to Emphasize Population Studied in Clinical Trials
Published: 2021-07-08 (Crawled : 12:00) - globenewswire.com
BIIB | $201.91 4.52% 4.32% 3.3M
|
Health Technology
|
| O: -1.48%
H: 5.71%
C: 5.42%
fda clinical trials trial fda approval
FDA grants accelerated approval for ADUHELM™ as the first and only Alzheimer’s disease treatment to address a defining pathology of the disease
Published: 2021-06-07 (Crawled : 18:00) - globenewswire.com
BIIB | $201.91 4.52% 4.32% 3.3M
|
Health Technology
|
| O: 3.22%
H: 58.64%
C: 34.03%
disease alzheimer treatment fda approval alzheimer’s alzheimer's disease alzheimer's
Biogen and Eisai launch multiple initiatives to help patients with Alzheimer’s disease access ADUHELM™
Published: 2021-06-07 (Crawled : 18:00) - globenewswire.com
CI | $352.28 -0.11% 0.0% 1.1M
|
Health Services
|
| O: 0.43%
H: 0.0%
C: -2.53%
BIIB | $201.91 4.52% 4.32% 3.3M
|
Health Technology
|
| O: 3.22%
H: 58.64%
C: 34.03%
disease alzheimer alzheimer’s alzheimer's disease alzheimer's
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.